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 Disorders of sexual development (DSD) are congenital 
conditions associated with atypical chromosomal, go-
nadal, or anatomical sex [Hughes et al., 2006]. Individuals 
with DSD and a 46,XY karyotype (46,XY DSD) due to 
disorders of testes development present different degrees 
of ambiguous genitalia and partial to complete testicular 
dysgenesis [Houk and Lee, 2008]. To date, various muta-
tions in several genes involved in sexual development, in-
cluding  SRY, NR5A1 (SF1), WT1, SOX9, DAX1 (NR0B1), 
DHH, WNT4, DMRT1/2, ATRX, and  MAP3K1 , have 
been described in these patients [Biason-Lauber, 2010; 
Barthold, 2011; Eggers and Sinclair, 2012], but in  ∼ 50% 
of cases with 46,XY DSD, the underlying genetic cause 
remains unknown.
 Laporte et al. [1997] identified the  MAMLD1 gene 
(mastermind-like domain-containing 1, previously 
 CXorf6 ) as a candidate gene for 46,XY DSD based on their 
observations of a contiguous gene syndrome in patients 
with myotubular myopathy and male hypogenitalism 
harboring deletions on chromosome Xq28 [Hu et al., 
1996; Laporte et al., 1997].
 In 2006,  MAMLD1 mutations were found in patients 
with severe hypospadias, a rather mild form of 46,XY 
DSD. Since this first description,  MAMLD1 mutations 
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 Abstract 
 MAMLD1 is suggested to play a role in the development of 
46,XY disorders of sexual development (46,XY DSD). So far, 
mutations in this gene have been detected in several cases 
of hypospadias with normal testosterone levels at birth. 
From in vitro studies it was concluded that  Mamld1 might 
transiently affect testosterone synthesis during genital de-
velopment. We describe the first  MAMLD1 mutation in a 
46,XY patient with complete gonadal dysgenesis. The novel 
 MAMLD1 missense mutation (p.P677L) results in a severely 
reduced transactivation in vitro of the promoter of the 
 MAMLD1 target gene HES3/Hes3. However, as knowledge 
about the functional role of  MAMLD1 in gonadal develop-
ment is limited, we suggest that additional factors (digenic 
or oligogenic cause) play a role in the development of com-
plete gonadal dysgenesis in this patient. 
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have been described in several patients with hypospadias 
[Fukami et al., 2006; Kalfa et al., 2008, 2012; Chen et al., 
2010]. Moreover, the S-S haplotype, which entails the 
presence of a double  MAMLD1 gene polymorphism 
(p.P359S and p.N662S), has been found to be more fre-
quent in patients with hypospadias than in controls [Chen 
et al., 2010; Kalfa et al., 2011; van der Zanden et al., 2012].
 Recently, a cohort of 70 children with severe non-syn-
dromic 46,XY DSD of unknown etiology has been screened 
for  MAMLD1  mutations. Two new mutations, p.S143X 
and p.P384L, have been found in 2 patients with hypoplas-
tic phallus and severe hypospadias [Kalfa et al., 2012].
 The  MAMLD1 gene codes for a 774 amino acid protein 
(NP_005482). Two splice variants have been identified: 
one including and one excluding exon 4. Both proteins 
are ubiquitously expressed, but the longer protein, con-
taining exon 4, is the major form [Fukami et al., 2006, 
2008]. Both MAMLD1/Mamld1 proteins contain the tar-
get sequence of the steroidogenic factor 1  (NR5A1, SF1) , 
which is a key regulator of genes involved in sexual devel-
opment [Hoivik et al., 2010; Köhler and Achermann, 
2010]. The MAMLD1 protein transactivates the promot-
er of a non-canonical Notch target gene hairy/enhancer 
of split 3  (Hes3) [Fukami et al., 2008; Ogata et al., 2008, 
2009; Nakamura et al., 2011].  HES/Hes family genes play 
a role in repressing/activating transcription factors in 
multiple tissues and are involved in tissue specific cell dif-
ferentiation during embryonic development [Kageyama 
et al., 2007; Katoh and Katoh, 2007, 2009].
 Concerning  MAMLD1 function in sex differentiation, 
Fukami et al. [2008] suggested a supportive role in testos-
terone production around the critical period for male sex-
ual development.
 Mamld1 mRNA expression levels have been shown to 
increase gradually between days E8.5 and E12.5 of embry-
onic development, and  Mamld1 expression has been 
found from E12.5 to E14.5 in fetal Leydig and Sertoli cells 
of male mice [Fukami et al., 2008; Miyado et al., 2012]. 
Transient knockdown of  Mamld1 in mouse Leydig tumor 
cells has demonstrated a reduction of testosterone pro-
duction and Cyp17a1 expression, an enzyme indispens-
able for testosterone synthesis in Leydig cells [Nakamura 
et al., 2011].
 Recently, a  Mamld1 knock-out (KO) male mouse has 
been studied. The KO mice display a partial decrease in 
mRNA levels of genes exclusively expressed in Leydig 
cells  (Star, Cyp11a1, Cyp17a1, Hsd3b1,  and Insl3) . How-
ever, their genital and reproductive development is com-
pletely normal. Species differences in sexual development 
have been suggested for the contradictive findings of gen-
ital phenotypes of  Mamld1 KO mice and patients with 
 MAMLD1 mutations [Miyado et al., 2012].
 A similar constellation could be found for the ste-
roidogenic factor 1  (NR5A1, SF1) .  Nr5a1  KO mice display 
complete gonadal and adrenal agenesis, whereas almost 
all humans with  NR5A1 mutations exhibit a wide range 
of gonadal dysgenesis and mostly normal adrenal devel-
opment and function [Jameson, 2004].
 Mamld1 expression in mice ovaries has been found in 
granulosa cells between 3 and 8 weeks of age [Ogata et al., 
2012]. Deletions in the Xq region (Xq13–Xq28), which 
contains  MAMLD1 , have been linked with premature 
ovarian failure [Rossetti et al., 2004; Ferreira et al., 2010]. 
However, the distinctive role of  MAMLD1/Mamld1 in 
ovarian development and function remains unknown.
 We hypothesized that  MAMLD1 mutations might also 
be involved in more severe forms of 46,XY DSD due to 
gonadal dysgenesis. In this study, we have performed a 
mutation screening of the  MAMLD1 gene in a cohort of 
patients with 46,XY DSD with partial to complete gonad-
al dysgenesis without known genetic cause.
 Patients and Methods 
 Patients 
 Thirty-five patients with 46,XY DSD and different degrees of 
ambiguous genitalia were screened for  MAMLD1 mutations. 
Twenty-three had partial and 12 had complete gonadal dysgenesis. 
Mutations of  SRY, NR5A1 (SF1), and  WT1 were previously ex-
cluded in these patients. Before performing genetic screening, in-
formed consent was obtained from each patient or legal guardian.
 Mutational Analysis 
 Genomic DNA was isolated from peripheral white blood cells 
using the Blood amp kit from Qiagen (Hilden, Germany). Coding 
exons and their flanking splice sites of the  MAMLD1 gene 
(NM_005491) were amplified using a standard PCR protocol. Prim-
ers for amplification are summarized in  table 1 . Sequencing was per-
formed using the BigDye Terminator v3.1 cycle sequencing kit (Per-
kin-Elmer, Weiterstadt, Germany) and run on an ABI 3710xl Auto-
matic Sequencer (Applied Biosystems, Foster City, Calif., USA).
 The number of amino acids of the MAMLD1 protein varies 
depending on the protein isoform studied. In this study, we used 
the protein variant of 774 amino acids (NP_005482) for number-
ing of new and previously described mutations.
 Functional Analysis 
 For functional characterization of the new mutation, its ability 
to activate the  Hes3 gene promoter was tested. Previously, the 
 MAMLD1 wild type has already shown a transactivation function 
of the  Hes3 promoter, while the p.E197X and p.S143X mutants 
have shown a greatly reduced transactivation capacity [Fukami et 
al., 2008; Kalfa et al., 2012].
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 A pCMV-Myc plasmid vector containing the  MAMLD1 full-
length cDNA, a pCMV-Myc vector containing the nonsense 
p.E197X mutation, and a reporter vector with the  Hes3 response el-
ement and a firefly luciferase gene were used for functional analysis.
 The p.P677L mutation was obtained by site-directed mutagen-
esis (QuikChange II Site-Directed Mutagenesis kit, Stratagene, La 
Jolla, Calif., USA) of the pCMV-Myc vector containing the wild-
type  MAMLD1 sequence.
 For transactivation analysis of the p.P677L mutation, a Dual-
Luciferase Reporter Assay System (Promega, Fitchburg, Wis., 
USA) was used. COS-7 cells were seeded in 6-well dishes (2.5 × 10 5 
cells/well) and were transiently transfected using Metafectene 
 (Biontex, Planegg, Germany) with 2 μg of luciferase reporter vec-
tor, 4 μg of pCMV-Myc expression vector containing either wild-
type  MAMLD1 , p.E197X or p.P677L mutant, and 2 μg of Renilla 
luciferase as an internal control. Transactivations of the wild-type 
and mutant proteins were compared, and an empty pCMV-Myc 
vector was used as a negative control.
 The cells were lysed 48 h after transfection, and the mouse  Hes3 
 promoter transactivation activity was measured. The assays were 
repeated 3 times in duplicates.
 Statistical data analysis was performed using GraphPad Prism 
5 (Graph Pad Software, La Jolla, Calif., USA). Results were consid-
ered significant if p < 0.05 using a one-way ANOVA and Tukey-
Kramer test.
 In silico Analysis 
 For in silico analysis of the mutation, the program Mutation 
Taster (www.mutationtaster.org), which employs a Bayes classifier 
to predict the disease potential of an alteration, was used [Schwarz 
et al., 2010].
 Results 
 A novel hemizygous c.2030C>T (p.P677L) mutation 
was found in a patient with 46,XY complete gonadal dys-
genesis ( fig. 1 ). The patient presented with primary amen-
orrhea at the age of 13 years. The external genitalia were 
completely female. No gonads could be detected, but the 
uterus was present. At diagnosis, the gonadotropins were 
elevated (FSH 76 U/l, LH 17.3 U/l). Estrogen level was low, 
and testosterone level was in the normal range for females.
 The mother was found to be a heterozygous carrier of 
the mutation, while the father displayed the wild-type al-
lele. The 41-year-old mother has not shown any impair-
ment of gonadal function, and her sexual hormone levels 
Table 1.  Primers used for MAMLD1 mutational screening
Forward Reverse Product size, 
bp
Exon 1 CCCTGTGTCTAGGTCGTTTGG CCTGCCACCAAGTTTGCACAG 263
Exon 2 GTAACAGTCTGATCTGTGCCTC GACCTCTTGTAGGTCCCTTTC 261
Exon 3, start GTGTGTGTCACCTCTCTTCCC GGGTGACATCTTCAAGGCAAGG 172
Exon 3, middle TGATGGGGGCTACCCTAATA GGCTCCGTGGCTCCTGGGCTG 1,300
Exon 3, end GTCGCTCTGCCCCCCTTACC CCAAAACAAAAGAACACAGCCAGATATG 1,050
Exon 4 CTTGACACCAGGGAGTTGGT ATGATTTGCATGACCCCAAT 385
Exon 5 CACTCAGGGCAGTGACAAGA GGCATACAGCTGAGGGAGAG 594
Exon 6 GCGAGTGTATGCTGGTGTGT TTGGGAACACTGGCCTTAAC 207
Exon 3, sequencing CCAAGCCTTCGGTTCAGATGTC
GAGCTCCATTCTTGCCAACCTC
–
 Additional primers were used for exon 3 sequencing.
* *
• GDVSPSNITHVDKACKLG    Homo sapiens (NP_005482)
• GHVPPSNLTHVDKACKLG   Mus musculus (XP_006528172.1)
• GDVSPSNITHVDKACKLG    Pan troglodytes (XP_521302.3)
• GDVSPSNITHVDKACKLG    Equus caballus (NP_001166929.1)
• GAVSPSNITHVDKACKLG   Physeter catodon (XP_007129627.1)
 Fig. 1. Chromatogram of the c.2030C>T (p.P677L) mutation. The 
wild-type sequence is shown on the left, and the hemizygous mu-
tated sequence is shown on the right. Arrows and asterisks indicate 
the affected nucleotide. 
 Fig. 2. MAMLD1 homologous protein sequence alignments 
around the mutation site (red) in different mammals. 
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are in the normal range. There is no family history of 
46,XY DSD or 46,XX DSD.
 The novel mutation p.P677L is located in a highly con-
served region of  MAMLD1/Mamld1 in mammals ( fig. 2 ). 
So far, the mutation is not described in the National Cen-
ter for Biotechnology Information (NCBI) single nucleo-
tide polymorphism (dbSNP) database, Exome Variant 
Server (http://evs.gs.washington.edu/EVS/), 1000 Ge-
nomes (http://browser.1000genomes.org/index.html), 
and ALFRED database (http://alfred.med.yale.edu/al-
fred/index.asp), and it was absent in 120 healthy controls.
 The in silico analysis of the mutation predicted it to be 
disease causing with a probability of 0.53.
 Accordingly, we tested the ability of the resulting mu-
tant protein to activate the promoter of its downstream 
partner  Hes3 in vitro. Functional characterization of the 
mutant p.P677L showed a significant loss of the transac-
tivation function on the  mouse  Hes3 promoter ( fig.  3 ) 
compared to the wild-type protein (p < 0.05).
 Discussion 
 This is the first report of a  MAMLD1 mutation in a pa-
tient with 46,XY DSD and complete gonadal dysgenesis. 
The novel hemizygous mutation (p.P677L) is located in a 
highly conserved region of  MAMLD1  and results in a 
nearly complete loss of transactivation of the promoter of 
 Hes3 , a target gene of MAMLD1 . So far,  MAMLD1 muta-
tions have only been described in patients with hypospa-
dias, a less severe phenotype of 46,XY DSD. Most patients 
display normal testosterone production after birth [Gas-
pari et al., 2011], and it is hypothesized that  MAMLD1 has 
only a transient effect on Leydig cell function and testos-
terone synthesis during embryonic development. So far, 
 MAMLD1  mutations have been identified in 11 out of 250 
cases with hypospadias (4.4%), and 5 of them have been 
functionally characterized: 3 nonsense mutations in exon 
3 (p.E197X, p.Q270X, and p.S143X) have shown a com-
plete loss of transactivation function, 1 missense mutation 
(p.P384L in exon 3) has shown a significant reduction in 
transactivation function, and 1 nonsense mutation (p.
R726X in exon 5) retains normal transactivating activity 
but seems to exert a deleterious effect through early deg-
radation by nonsense-mediated mRNA decay. To date, no 
correlation has been found between the severity of the 
phenotype and complete or partial loss of transactivation 
activity ( table 2 ;  fig. 4 ) [Fukami et al., 2006; Kalfa et al., 
2008, 2011].
 So far, all studies investigating the function of 
 MAMLD1 mutations in vitro have used the mouse  Hes3 
 promoter as a target gene, as no other target genes of 
MAMLD1 are known.
 The  Hes3 gene belongs to the  Hes/Hey gene family in-
volved in processes of maintenance of stem cells, binary 
cell fate decisions, and timing of developmental events in 
the embryo [Kageyama et al., 2007; Katoh and Katoh, 
2007]. Therefore, factors influencing a correct expression 
of these regulators could hypothetically also affect early 
sexual development.  HES3 has been found to be expressed 
in human fetal testes and adult ovaries [Fukami et al., 
2008]. Furthermore,  Hes3 is a target of a non-canonical 
Notch signaling pathway, and Notch receptors have been 
proven to be expressed in mouse testes and regulate their 
development [Tang et al., 2008].
 The presence of a functionally relevant  MAMLD1 mu-
tation in our patient suggests that  MAMLD1 might be 
involved not only in testosterone synthesis of the Leydig 
cells but also in gonadal development. However, we only 
hypothesize that the  MAMLD1 mutation contributes to 
the severe phenotype of complete gonadal dysgenesis in 
our patient as knowledge about the role of  MAMLD1/
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 Fig. 3. Transactivation of the promoter of the MAMLD1 target 
gene  Hes3 by MAMLD1 WT, p.E124X, and p.P677L cloned into 
the pCMV-Myc vector. Data are shown as mean (columns) and 
standard error of the mean (bars). p.P677L, p.E124X, and the emp-
ty vector showed a statistically significant reduction of transactiva-
tion function compared to MAMLD1 WT (p < 0.05). WT = Wild 
type. 
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Mamld1 in gonadal development and function is still lim-
ited.
 The phenotype of our patient might be caused by a di-
genic or oligogenic pathogenic mechanism where the in-
teraction of 2 or more loci is needed for the expression of 
a certain phenotype. One well-known example of this 
complex genetic background is congenital hypogonado-
tropic hypogonadism where new genes involved in its 
 oligogenic inheritance have been recently discovered 
[Miraoui et al., 2013]. In the case of Kallman syndrome, 
consisting of hypogonadism and anosmia, a digenic mode 
of inheritance has been proven in a few patients. These 
patients carry heterozygous mutations in 2 different 
genes  (PROKR2  and  PROK2 or  PROK2 and  KAL1)  [Dodé 
and Rondard, 2013].
 Digenic mutations have also been described in some 
rare diseases, such as retinitis pigmentosa, long QT syn-
drome, Bardet-Biedl syndrome, or deafness [Dodé and 
Rondard, 2013; Schäffer, 2013].
 Subsequently, we suggest that until further insight is 
gained into  MAMLD1  function, other factors or muta-
tions in so far unknown genes are very likely to be in-
volved in the development of the complete gonadal dys-
genesis in our patient. In particular, digenic or oligogenic 
mutations should be considered being a possible underly-
ing cause of disorders of gonadal development.
E197X Q270X R726XP677LS143X
1 2 3 4 5 6 7
P384L
Table 2.  Reported MAMLD1 mutations in 46,XY DSD patients
Reference Mutation Age Genital phenotype Testosterone, 
nmol/l
DHT, 
nmol/l
AMH, 
ng/ml
Inhibin B, 
ng/ml
Transactivation 
function
Fukami et al. 
[2006]
p.E197X
(prev. p.E124X)
4 months hypospadias with chordee, 
inguinal testis
<0.3 0.07 _ _ abolished
Fukami et al. 
[2006]
p.E197X
(prev. p.E124X)
1 month hypospadias with chordee, 
scrotal testis
0.7 <0.15 _ _ abolished
Fukami et al. 
[2006]
p.Q270X
(prev. p.Q197X)
2 years hypospadias with chordee, 
scrotal testis
0.1 _ _ _ abolished
Fukami et al. 
[2006]
p.R726X
(prev. p.R653X)
1 month hypospadias with chordee, 
retractil testis
0.3 _ _ _ normal
Kalfa et al. 
[2008]
p.V505A
(prev. p.V432A)
5.5 years hypospadias with chordee, 
scrotal testis
_ _ _ _ normal, Ogata 
et al. [2012]
Kalfa et al. 
[2008]
c.544delG
(prev. c.325delG)
1 year hypospadias with chordee <0.06 <2 _ _ n.d.
Kalfa et al. 
[2008]
c.544delG
(prev. c.325delG)
1 year 2 months hypospadias with chordee _ _ _ n.d. n.d.
Kalfa et al. 
[2008]
p.Q604_Q605insQQQ
(prev. p.Q531_
Q532insQQQ)
1 month isolated hypospadias, 
coronal meatus
_ _ _ _ n.d.,
present in 
normal 
individuals, 
Chen et al. 
[2010]
Chen et al. 
[2010]
p.Q602K
(prev. p.Q529K)
_ severe hypospadias, 
bilateral cryptorchidism
_ _ _ _ n.d.
Kalfa et al. 
[2012]
p.S143X neonate scrotal hypospadias, 
microphallus, scrotal testis
5.9 _ 336 _ abolished
Kalfa et al. 
[2012]
p.P384L neonate posterior hypospadias 
with chordee, microphallus, 
scrotal testis
<0.23 _ 19 <15 reduced
Present case p.P677L 13 years female external genitalia undetectable _ _ _ abolished
 Fig. 4. Location of previously described 
 MAMLD1 mutations and the new p.P677L 
mutation. An impairment of transactiva-
tion function was demonstrated in all mu-
tations shown (except for p.R726X). The 
boxes represent the exons. Black colored 
areas denote protein-coding regions and 
white areas are untranslated regions. 
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 Notably, in our patient the mutation was transmitted 
by the mother. Maternal transmission of  MAMLD1 mu-
tations has been described in 3 more cases [Ogata et al., 
2012]. Subsequently, maternal transmission of  MAMLD1 
mutations should be considered in a familial occurrence 
of 46,XY DSD.
 In conclusion,  MAMLD1 mutations are involved in 
the development of 46,XY DSD. It is hypothesized that 
 MAMLD1 mutations might contribute to the develop-
ment of severe forms of 46,XY DSD through a multiple 
loci interaction manner. However, the distinct function 
of  MAMLD1 in gonadal development and function in hu-
mans has still to be elucidated.
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